Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Current Hematologic Malignancy Reports
Published in: Current Hematologic Malignancy Reports 4/2016

01-08-2016 | Health Economics (N Khera, Section Editor)

Exploring Big Data in Hematological Malignancies: Challenges and Opportunities

Authors: Gustavo F. Westin, Ajoy L. Dias, Ronald S. Go

Published in: Current Hematologic Malignancy Reports | Issue 4/2016

Login to get access

Abstract

Secondary analysis of large datasets has become a useful alternative to address research questions outside the reach of clinical trials. It is increasingly utilized in hematology and oncology. In this review, we provided an overview of some examples of commonly used large datasets in the USA and described common research themes that can be pursued using such a methodology. We selected a sample of 14 articles on adult hematologic malignancies published in 2015 and highlighted their contributions as well as limitations.
Literature
1.
Call TG et al. Incidence of chronic lymphocytic leukemia in Olmsted County, Minnesota, 1935 through 1989, with emphasis on changes in initial stage at diagnosis. Mayo Clin Proc. 1994;69(4):323–8.CrossRefPubMed
2.
3.
Shanafelt TD et al. Impact of ibrutinib and idelalisib on the pharmaceutical cost of treating chronic lymphocytic leukemia at the individual and societal levels. J Oncol Pract. 2015;11(3):252–8.CrossRefPubMed
4.
5.
Winn AN et al. The real world effectiveness of hematopoietic transplant among elderly individuals with multiple myeloma. Journal of the National Cancer Institute. 2015;107(8):djv139. doi:10.​1093/​jnci/​djv139.
6.•
Shah GL et al. Cost-effectiveness of autologous hematopoietic stem cell transplantation for elderly patients with multiple myeloma using the surveillance, epidemiology, and end results—Medicare database. Biol Blood Marrow Transplant. 2015;21(10):1823–9. SEER-based study showed that autologous HSCT is cost-effective when compared to non-transplantation care in elderly patients with MM.CrossRefPubMed
7.
Hoppe RT, A.R., Bierman PJ et al, Hodgkin disease/lymphoma: clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2015;13(5):554–86.
8.
Siegel R, D.C., Virgo K et al. Cancer treatment and survivorship statistics, 2012. Cancer J Clin, 2012. 62: 220–241.
9.
Franklin J et al. Second malignancy risk associated with treatment of Hodgkin’s lymphoma: meta-analysis of the randomised trials. Ann Oncol. 2006;17(12):1749–60.CrossRefPubMed
10.
Aleman BM et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood. 2007;109(5):1878–86.CrossRefPubMed
11.
Canellos GP et al. Treatment of favorable, limited-stage Hodgkin’s lymphoma with chemotherapy without consolidation by radiation therapy. J Clin Oncol. 2010;28(9):1611–5.CrossRefPubMed
12.
Herbst C et al. Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin’s lymphoma: a systematic review. Haematologica. 2010;95(3):494–500.CrossRefPubMed
13.
Meyer RM et al. ABVD alone versus radiation-based therapy in limited-stage Hodgkin’s lymphoma. N Engl J Med. 2012;366(5):399–408.CrossRefPubMed
14.•
Olszewski AJ, Shrestha R, Castillo JJ. Treatment selection and outcomes in early-stage classical Hodgkin lymphoma: analysis of the National Cancer Data Base. J Clin Oncol. 2015;33(6):625–33. Population study utilizing the NCDB database showed evidence suggesting that CMT abandonment can be detrimental in early stage HL survival.CrossRefPubMed
15.
Attal M et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. New Engl J Med. 1996;335(2):91–7.CrossRefPubMed
16.
Lenhoff S et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group. Blood. 2000;95(1):7–11.PubMed
17.
Kristinsson SY, Anderson WF, Landgren O. Improved long-term survival in multiple myeloma up to the age of 80 years. Leukemia. 2014;28(6):1346–8.CrossRefPubMed
18.
Turesson I et al. Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study. J Clin Oncol. 2010;28(5):830–4.CrossRefPubMed
19.
Vij R et al. Impact of pretransplant therapy and depth of disease response before autologous transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2015;21(2):335–41.CrossRefPubMed
20.
Costa LJ, Gonsalves WI, Kumar SK. Early mortality in multiple myeloma. Leukemia. 2015;29(7):1616–8.CrossRefPubMed
21.
Sanchorawala V et al. Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience. Blood. 2015;126(20):2345–7.CrossRefPubMed
22.
Jaccard A et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. New Engl J Med. 2007;357(11):1083–93.CrossRefPubMed
23.
Gertz MA et al. Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis. Bone Marrow Transplant. 2013;48(4):557–61.CrossRefPubMed
24.•
D'Souza A et al. Improved outcomes after autologous hematopoietic cell transplantation for light chain amyloidosis: a Center for International Blood and Marrow Transplant Research study. J Clin Oncol. 2015;33(32):3741–9. Utilizing data from the CIBMTR the authors demonstrated that in recent years post-transplantation mortality in AL significantly improved, and center expertise with AL transplantation was important in reducing early mortality.CrossRefPubMed
25.
Go RS. Monoclonal gammopathy of undetermined significance: to screen or not to screen for multiple myeloma? Br J Haematol. 2010;149(4):620–1. Author reply 621-3.CrossRefPubMed
26.
Go RS, Gundrum JD, Neuner JM. Determining the clinical significance of monoclonal gammopathy of undetermined significance: a SEER-Medicare population analysis. Clin Lymphoma Myeloma Leuk. 2015;15(3):177–86. e4.CrossRefPubMed
27.
Feugier P et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005;23(18):4117–26.CrossRefPubMed
28.
29.
Odejide OO, et al. Hospice use among patients with lymphoma: impact of disease aggressiveness and curability. J Natl Cancer Inst. 2016. 108(1).
30.
Ferreri AJ et al. Enteropathy-associated T-cell lymphoma. Crit Rev Oncol Hematol. 2011;79(1):84–90.CrossRefPubMed
31.
Karanam PK, Al-Hamadani M, Go RS. Enteropathy-associated T-cell lymphoma in the US: higher incidence and poorer survival among Asians. Br J Haematol. 2015.
32.
Halm EA, Lee C, Chassin MR. Is volume related to outcome in health care? A systematic review and methodologic critique of the literature. Ann Intern Med. 2002;137(6):511–20.CrossRefPubMed
33.
Giri S et al. Impact of hospital volume on outcomes of patients undergoing chemotherapy for acute myeloid leukemia: a matched cohort study. Blood. 2015;125(21):3359–60.CrossRefPubMed
34.
National Cancer Institute. SEER stat fact sheets: acute myeloid leukemia. Bethesda, MD:. Available from URL: http://​seer.​cancer. gov/statfacts/html/amyl.html. 2013 [cited 2015 February].
35.
Medeiros BC et al. Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States. Ann Hematol. 2015;94(7):1127–38.CrossRefPubMedPubMedCentral
36.
Smith A et al. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer. 2011;105(11):1684–92.CrossRefPubMedPubMedCentral
37.
Pfreundschuh M et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7(5):379–91.CrossRefPubMed
38.
Coiffier B et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235–42.CrossRefPubMed
39.•
Williams JN et al. Disease characteristics, patterns of care, and survival in very elderly patients with diffuse large B-cell lymphoma. Cancer. 2015;121(11):1800–8. Largest study to date evaluating treatment patterns and outcomes in patients with DLBCL aged >80 years showed that elderly patients treated with R-CHOP had the longest survival, however, were less likely to receive this treatment combination when compared to younger patients.CrossRefPubMedPubMedCentral
40.
Rubin DB. Matching to remove bias in observational studies. Biometrics 29.1 (1973): 159–183. Web…
41.
Bender R. Introduction to the use of regression models in epidemiology. Methods Mol Biol. 2009;471:179–95.CrossRefPubMed
42.
Ross ME et al. Propensity score methods for analyzing observational data like randomized experiments: challenges and solutions for rare outcomes and exposures. Am J Epidemiol. 2015;181(12):989–95.CrossRefPubMed
43.
Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1997;127(8 Pt 2):757–63.CrossRefPubMed
44.
Greenland S. An introduction to instrumental variables for epidemiologists. Int J Epidemiol. 2000;29(6):1102.CrossRefPubMed
45.
46.
Shah A et al. Building a rapid learning health care system for oncology: why CancerLinQ collects identifiable health information to achieve its vision. J Clin Oncol. 2016;34(7):756–63.CrossRefPubMed
47.
48.
Robbins AS et al. Association between the affordable care act dependent coverage expansion and cervical cancer stage and treatment in young women. JAMA. 2015;314(20):2189–91.CrossRefPubMed
49.
Zhu J et al. Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancer. JAMA. 2012;307(15):1593–601.CrossRefPubMedPubMedCentral
50.
Carroll NM et al. Use of bevacizumab in community settings: toxicity profile and risk of hospitalization in patients with advanced non-small-cell lung cancer. J Oncol Pract. 2015;11(5):356–62.CrossRefPubMed
51.
52.
Pollack LA et al. Care of long-term cancer survivors: physicians seen by Medicare enrollees surviving longer than 5 years. Cancer. 2009;115(22):5284–95.CrossRefPubMed
53.
McWilliams JM et al. Geographic variation in cancer-related imaging: Veterans Affairs health care system versus Medicare. Ann Intern Med. 2014;161(11):794–802.CrossRefPubMedPubMedCentral
54.
Pachman DR et al. Calcium and magnesium use for oxaliplatin-induced neuropathy: a case study to assess how quickly evidence translates into practice. J Natl Compr Canc Netw. 2015;13(9):1097–101.PubMed
55.
Greif JM et al. Gender differences in breast cancer: analysis of 13,000 breast cancers in men from the National Cancer Data Base. Ann Surg Oncol. 2012;19(10):3199–204.CrossRefPubMed
56.
57.
58.
Charlton ME et al. Is travel time to colonoscopy associated with late-stage colorectal cancer among Medicare beneficiaries in Iowa? J Rural Health. 2015. doi:10.​1111/​jrh.​12159.
59.
Dimick J et al. Black patients more likely than whites to undergo surgery at low-quality hospitals in segregated regions. Health Aff. 2013;32(6):1046–53.CrossRef
Metadata
Title
Exploring Big Data in Hematological Malignancies: Challenges and Opportunities
Authors
Gustavo F. Westin
Ajoy L. Dias
Ronald S. Go
Publication date
01-08-2016
Publisher
Springer US
Published in
Current Hematologic Malignancy Reports / Issue 4/2016
Print ISSN: 1558-8211
Electronic ISSN: 1558-822X
DOI
https://doi.org/10.1007/s11899-016-0331-4

Other articles of this Issue 4/2016

Current Hematologic Malignancy Reports 4/2016 Go to the issue

Health Economics (N Khera, Section Editor)

Scientific Achievements May Not Reach Everyone: Understanding Disparities in Acute Leukemia

Health Economics (N Khera, Section Editor)

Oral Chemotherapy in Patients with Hematological Malignancies—Care Process, Pharmacoeconomic and Policy Implications

Health Economics (N Khera, Section Editor)

Bending the Cost Curve in Childhood Cancer

CART and Immunotherapy (M Ruella, Section Editor)

T-Cell Receptor-Engineered Cells for the Treatment of Hematologic Malignancies

CART and Immunotherapy (M Ruella, Section Editor)

Planes, Trains, and Automobiles: Perspectives on CAR T Cells and Other Cellular Therapies for Hematologic Malignancies

Health Economics (N Khera, Section Editor)

Value Based Care and Patient-Centered Care: Divergent or Complementary?

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24 to hear Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits